Metformin Use Linked to Lower Bladder Cancer Risk: Meta-Analysis of 6.3 Million People with Diabetes
A review of 14 studies covering ~6.3 million people with type 2 diabetes: metformin users developed bladder cancer about one-third less often; pioglitazone and SGLT2 inhibitors showed no clear link.
By Sanare Lab · September 23, 2026 · 2 min read
Key Takeaway
A large review of 14 studies covering about 6.3 million people with type 2 diabetes found that people taking metformin developed bladder cancer about one-third less often. Two other diabetes drug families checked — pioglitazone and SGLT2 inhibitors — showed no clear link either way. This is real-world observation, not proof of prevention.
Type 2 diabetes raises the risk of bladder cancer, and whether individual diabetes drugs push that risk up or down has been debated for years. A review published in Urologia on September 17, 2026 (Mathez and colleagues) gathered all 14 available observational studies — research that watches real life rather than testing a treatment — covering roughly 6.3 million people.
The Numbers
Metformin: pooled relative risk 0.67 — in the combined data, bladder cancer was diagnosed about one-third less often in users (95% confidence interval, the margin of statistical uncertainty: 0.46–0.98). However, the studies differed a lot from one another, which weakens certainty. Pioglitazone: no clear link overall (relative risk about 1.05), although several studies hinted that long-term, high-dose use might raise risk. SGLT2 inhibitors, a newer class of diabetes drugs: no increased-risk signal (0.98). For how repurposed drugs are dosed in practice, see our dosing calculator; broader context: our long-reads on the Care Oncology Protocol (metformin combined with other repurposed drugs) and on ivermectin plus metformin in breast cancer.
In plain words
What happened: A review combined 14 observational studies covering about 6.3 million people with type 2 diabetes and compared bladder cancer rates by diabetes medicine use.
Why it matters: Researchers asked whether commonly used diabetes medicines were linked to different bladder cancer rates in real-world records.
How strong is the evidence: The review found lower rates among metformin users, but observational studies cannot prove the drug prevented cancer or rule out other explanations.
What it means for you: Do not start metformin to prevent bladder cancer. If you take diabetes medicine, discuss any changes with your prescribing clinician.
References
- Mathez W, Vincentelli A, Chaoui I, Bruyère F, Bourgi A. Antidiabetic drug exposure and risk of bladder cancer: A systematic review and meta-analysis. Urologia. 2026 Sep 17. doi:10.1177/03915603261486088. PMID: 42755180.
Medical Disclaimer
This article is for informational purposes only and is not medical advice, diagnosis, or a treatment recommendation. The study described reviews real-world data on cancer risk in people with type 2 diabetes — it is not a treatment trial and not a basis for starting, stopping or changing any medication. Always consult a licensed healthcare provider.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.